You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
憧憬產品於內地加快使用疫苗股受捧 開拓藥業-B(09939.HK)飆34%
藍籌石藥(01093.HK)針對新冠變異病毒株自主研發的mRNA疫苗獲準在內地開展臨牀研究,今日初段(4日)曾急漲11%,高見9.79元;現升5%,報9.29元。憧憬其餘新冠疫苗於內地加快使用,相關股也受捧,尤其是開拓藥業-B(09939.HK)一舉升破20天、50天及10天線,最高見14.54元,現報13.68元,飆升34%,成交增至1,790萬股。復星醫藥(02196.HK)高見44.2元,創逾半年高,現報43.5元,急漲11.5%。康希諾生物-B(06185.HK)重越20天線,最高見140元,現報132.2元,回升5.3%。藍籌藥明生物(02269.HK)升逾6%,報69.9元。金斯瑞生物(01548.HK)回升5.9%報25.9元。騰盛博藥-B(02137.HK)回升4.6%報11.48元。國藥(01099.HK)續升2.9%報18.44元,股價重越50天線(18.4元)。 此外,歌禮制藥-B(01672.HK)已在港遞新冠藥Paxlovid上市許可申請,其重越10天線(5.4元),盤中最高見6.25元,創逾兩個月高,現報5.81元,回升約14%。藥明康德(02359.HK)更急彈10.8%報137.6元即市高位,股價升破百天線(128.25元)。康方生物-B(09926.HK)回升8.5%報16.86元,股價升破20天線(16.5元)。百濟神州(06160.HK)回升5.1%報123.9元,股價重越50天線(122.6元)。信達生物(01801.HK)續升6.6%報28.95元,股價重越20天(27.5元)及10天線(28.5元)。 威高股份(01066.HK)續升4.5%報8.78元。聯邦製藥(03933.HK)及四環醫藥(00460.HK)升3.9%及3.1%,報4.29元及1.62元。三生醫藥(01530.HK)曾高見6.71元創近兩個月高,現升逾2%,現報6.58元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account